Mouse myocardial ischemia-reperfusion models are an effective method for cardiovascular research to simulate clinical acute or chronic heart disease13,14. Significant effort has been applied to develop and refine surgical approaches that produce ischemic events and reperfusion damage in the hearts of several different animal types. While there are particular advantages to the use of different animals systems, the mouse has characteristics that have led to extensive interest in producing myocardial I/R in the mouse heart. One of the major reasons is the genetic tractability of the mouse system. The extensive selection of genetically modified animals available, and the relative ease by which new models can be generated to address specific questions, have no match in other animal model systems. Another reason for the increasing use of mice in cardiovascular studies is the increasing availability of surgical equipment and other experimental tools specifically designed for use in mice. The relatively low cost of mouse models is also an important contributor to their use in studies. The increasing need for rigor in preclinical studies necessitates the use of additional animals, which can be more realistic when fewer resources are necessary to include the appropriate number of animals. While the use of the mouse model has several advantages there are disadvantages as well, particularly when considering the divergent aspects of mouse and human cardiovascular physiology. Many larger animal models, such as the dog and pig, more closely mimic most aspects of human cardiovascular physiology than the mouse. Another disadvantage is the size of the mouse, manipulation of the smaller heart in the mouse requires a higher degree of surgical skill, particularly in locating the LAD and reproducibly ligating it to produce a consistent infarct area in the left ventricle. The method presented here can provide a significant improvement in identification and ligation of the LAD. Our consistent results in the amount of cTnI release from the heart (Figure 2) suggest that we can reproducibly generate infarct of a similar size and level of cardiomyocytes death.
A key aspect of surgeries to induce experimental myocardial infarct is the clear identification and ligation of the LAD. In our approach detailed here we have improved the methodology to identify and access the LAD, allowing for more consistent positioning of the ligation on the vessel. During the surgery, we make use of a small piece of sterile cotton to lift the left atrium up and fully expose the LAD, which clarifies the position of LAD and facilitates the ligation of LAD. This a critical step for the technique and a differentiation point from other approaches. The introduction of these modifications for LAD ligation should allow for more reproducible results during simulation of MI in mouse models. While improved precision in the placement of the ligature should improve consistency in the size of infarct generated it is still important to measure the at risk zone using perfusion of Phthalo Blue dye. This is particularly true during the use of genetic modification mouse lines where the manipulation of gene expression can result in changes in the response of the blood vessels of the heart to ligation.
Another critical step during ligation in confirming that ischemia has been effectively generated by the ligation of the LAD. Observation of a distinct, rapid color change in the area of risk is essential to be certain that ischemic conditions have been produced in the targeted section of the myocardium. The change in color of the myocardium should be seen within a few seconds if the LAD is effectively occluded. Other critical steps in the procedure involve the duration of the ischemic period and the time allowed for reperfusion before experimental endpoints are measured. As mentioned in the protocol, the length of the ischemic period can be varied to produce different degrees of ischemic damage to the heart. Generally a longer period of ischemia will result in more extensive myocyte death throughout the risk zone. The length of reperfusion can have effects on the development of cardiac pathology, including the appearance of fibrotic lesions in the heart as well as the stabilization of cardiac output and electrophysiological changes. Thus, the specific length of these experimental steps must be tailored to address the specific questions examined in the study. The experimental endpoints should also be selected based on the length of ischemia and reperfusion periods used and the specific questions to be addressed in the experiment. We present the use of TTC staining to measure infarct size and ELISA measurements of serum CTnI levels as endpoints to assess the extent of cardiac damage. These endpoints can be used for any length of reperfusion, however they are particularly useful for shorter reperfusion periods (24 hours) where functional defects may not have stabilized yet. While we do not go into detail here on functional measurements of cardiac output, such as Doppler echocardiography15 and microsphere measurements of coronary blood flow16, these approaches are useful to understand the changes in cardiac function during longer term experiments, such as chronic occlusion of the LAD.
While the use of mouse models of MI have great advantages for the study of I/R injury in the heart there are still limitations to these approaches. Since major surgical incisions must be made into the chest cavity the resulting tissue disruptions and associated inflammation can influence the response of the heart to the MI effects. These concerns can be partially addressed through the use of sham surgical control mice, where all the surgical steps are all conducted with the exception of the tightening of the ligature around the LAD. Another issue that is produced by the invasive nature of the surgery is the need to manage the pain and suffering that occurs during and after the procedure. Pain management approaches that conform to current best practices are detailed in this procedure and are necessary to prevent suffering of the experimental animals. It is important to be aware that the use of many different types of anesthetics and analgesics can have cardioprotective effects following their application. Thus, it appropriate to apply these agents to the control mice, even any control mice that are not used for sham surgeries, in order to avoid any complications to interpretation of experimental results. Another limitation to this approach is that it does not provide a perfect simulation of pathology associated with human MI. Frequently the mouse models used for such experiments do not suffer from co-morbidities that underlie the MI in humans, such as coronary vascular disease, diabetes and hypertension. Such complications that are not present in the mouse model could have effects on the pathways being studied in a particular experiment and should therefore be considered when interpreting results. In these cases, the use of genetically modified mice that display some of these underlying pathologies may be appropriate to more effectively model the disease as it would present in human patients. In the future, other aspects of this approach could be modified to more accurately simulate additional aspects of human MI pathology.
Despite these limitations, the methods described here represent an effective approach to produce localized I/R injury in the mouse that simulates much of the pathologic effects of MI in human patients. Our technique allows for easier manipulation of the LAD that can lead to more reproducible results and simplify the surgery. However, mastering this technique still requires significant surgical skill that can only be gained through practice of the procedure. Taking sufficient care when conducting the surgery, particularly at places where this is noted in the protocol, will improve the survival rate of animals as well and the reproducibility of the experimental results. Once the surgical approach is mastered, this protocol will prove quite useful to investigators studying the effect of MI on cardiovascular physiology as well as those interested in testing the efficacy of therapeutic interventions on a mouse model.